Abstract MicroRNAs (miRNAs) are short, non-coding RNAs that employ classic Watson-Crick base-pairing to identify their target genes, ultimately resulting in destabilization of their target mRNAs and/or inhibition of their translation. The role of miRNAs in a wide range of human diseases, including those afflicting the kidney, has been intensely investigated. However, there is still a vast dearth of knowledge regarding their specific mode of action and therapeutic effects in various kidney diseases. This review discusses the latest efforts to further our understanding of the basic biology of miRNAs, their impact on various kidney diseases and their potential as novel biomarkers and therapeutic agents. We initially provide an overview of miRNA biology and the canonical pathway implicated in their biogenesis. We then discuss commonly employed experimental strategies for miRNA research and highlight some of the newly described state-of-the-art technologies to identify miRNAs and their target genes. Finally, we carefully examine the emerging role of miRNAs in the pathogenesis of various kidney diseases.
Introduction
Non-coding RNAs (ncRNAs) comprise multiple classes of RNAs that by definition are not transcribed into proteins. To date, the most intensely studied ncRNAs are microRNAs (miRNAs). miRNAs are small [usually 19-24 nucleotides (nt)], non-coding, single-stranded RNAs that provide a new layer of gene regulation [1, 2] (Fig. 1) . They inhibit the expression of messenger RNAs (mRNAs) primarily by pairing with the 3′-untranslated region (UTR) of their complementary mRNAs, causing translational repression and/or mRNA cleavage. miRNAs are largely evolutionarily conserved among species and commonly participate in the regulation of diverse cellular processes, including apoptosis, proliferation, hematopoiesis and angiogenesis, [3] .
During the past decade, it has become increasingly apparent that miRNAs are causally linked to a variety of human diseases, including cancer, heart disease and diabetes [4] . The crucial role of miRNAs in the development of kidney diseases has been widely recognized. This is of no surprise considering that an individual microRNA can often regulate the expression of multiple target genes. Thus, dysregulation of a single microRNA can, in principle, influence an entire gene network and thereby contribute to the complex disease phenotypes commonly observed in a variety of kidney diseases.
Discovery of miRNAs
One of the major advances in biology within the last decade has undoubtedly been the discovery of both small and large regulatory RNAs, including miRNAs which are among the best characterized group of this newly discovered regulatory class of RNAs [5] .
Lee et al. initially described the first reported miRNA, lin4, as a novel, non-protein-coding gene that served as a regulator of developmental timing in Caenorhabditis elegans [6] . In simultaneously publications, Lee et al. [6] and Wightman et al. [7] separately reported that the target protein-coding gene lin14 was negatively regulated by lin4 through interactions at the 3′-UTR of lin14. Thereafter, Reinhart et al. reported a similar discovery of a small RNA in C. elegans, let7, whose target gene, lin28, was also essential in maintaining proper developmental timing in C. elegans [8] . Both lin4 and let7 were considered to be unique and did not enjoy a great deal of attention for an extended period of time. However, the significance of these two supposedly isolated genes became relevant several years after their initial discovery when several research groups almost simultaneously reported that this obscure family of non-protein-coding genes were indeed highly evolutionarily conserved among several species, including humans [9] [10] [11] [12] . This was quickly followed by several groups convincingly demonstrating the basic steps of miRNA biogenesis, its modes of actions and ultimately its importance to human health and disease [2, 13] .
The discovery of miRNAs in diverse species raised the question of what these tiny non-coding RNAs may be doing in the cell and whether they play any roles in disease processes. In this regard, Calin et al. made the first association between microRNA dysregulation and cancer. In their landmark study, miR-15 and -16, were found to be significantly upregulated in patients with B-cell leukemia [14] . These early association studies were followed-up by other groundbreaking studies which focused on the effect(s) of global miRNA deletion [15] [16] [17] [18] . The results of these and other investigations led to the conclusion that miRNAs are dysregulated in almost all types of human cancer and that specific signatures of aberrantly expressed miRNAs harbor diagnostic, prognostic and therapeutic implications.
Biogenesis and mode of action
Mature miRNAs are evolutionarily conserved single-stranded RNAs. The generation of mature miRNAs is a multi-step process that starts with the initial transcription of their genes by RNA polymerase II into a long primary microRNA (primiRNA) (Fig. 2 ). The nuclear pri-miRNA, which can be several hundred to several kilobases long, is then processed by two enzymes, Drosha and its binding partner DiGeorge syndrome critical region gene 8, into a 70-to 80-nt-long precursor miRNA (pre-miRNA) [19, 20] . The pre-miRNA is exported from the nucleus utilizing the Ran-Gap/exportin-5 transport system into the cytoplasm [21] where it undergoes a final processing step by the RNAse III enzyme Dicer. Dicer cleaves the pre-miRNA into a 20-to 22-nt-long, doublestranded mature miRNA and subsequently facilitates loading of a single active strand of the mature miRNA into the RNA induced silencing complex (RISC) [22] . Here the mature miRNA is bound to the Argonaute family of proteins, thereby exposing the 5′ seed sequence of the mature miRNA and targeting the miRNAs to the target mRNA [23] . At each step of miRNA biogenesis, several proteins contribute to the ability of Drosha and Dicer to accurately recognize sequencespecific features of pri-, pre and mature miRNAs to facilitate proper cleavage and maturation of biologically active miRNA. These different maturation steps are critical to maintain proper miRNA levels in order to prevent cellular abnormalities [24] . Once bound to its target mRNA, the RISC complex can facilitate several forms of transcriptional repression depending on the strength of the miRNA-mRNA interaction and seed-sequence/target site complementarity. Protein expression of the target mRNA can be blocked by miRNA/ RISC complexes through several mechanisms, including ribosome stalling along on the mRNA, ribosomal dropoff, translation initiation repression, target mRNA degradation and mRNA deadenylation [25, 26] . Interestingly, miRNA-RISC targeting is not exclusive to the cytoplasm where the majority of mRNA is exported for protein translation. Indeed, miRNA-RISC shuttling between the cytoplasm and nucleus has been shown for several miRNAs, which elicit their activity The 70-to 80-nucleotide (nt)-long, double stranded, precursor-miRNA is cleaved by Dicer at the stem-loop sequence into a single-stranded, 20-to 22-nt-long mature miRNA. This mature miRNA is subsequently loaded into an RNA induced silencing complex (RISC), where it exerts its gene regulatory activity. Highlighted in red is the 5-to 8-nt miRNA seed sequence, which is complementary to target mRNAs and the responsible element for miRNA:mRNA interactions within the nucleus to regulate the expression of pri-miRNAs and other target genes [23, 27, 28] . Additional nuclear roles of miRNAs have been demonstrated to include direct DNA binding of miRNAs to promoter regions of genes to functionally regulate gene transcription of certain genes, in either a gene-activating or gene-repressive manner [25] .
In 2008, it was discovered that miRNAs are also present in blood, where they can act much like hormones in an endocrine system [29, 30] . Indeed, circulating miRNAs can be transported in microparticles (exosomes, microvesicles) or, alternatively, they can be directly released into blood in response to injury, chronic inflammation or apoptosis [31] . Circulating miRNAs enter the bloodstream and are taken up by the cells via endocytosis where they can identify their targets and exert their effects on the recipient cells.
miRNA levels are meticulously regulated at both transcriptional and post-transcriptional levels. With regards to their transcriptional regulation, miRNAs have been shown to utilize host gene promoters or to possess their own unique promoter elements upstream of the pri-miRNA putative transcription start sites [32] . Approximately one-third of intronic miRNAs are transcribed independently of their host genes [32, 33] . miRNA promoters harbor elements that resemble traditional Pol II promoters and typically contain enhancer-like elements upstream of transcriptional start sites [34, 35] promoters add an additional level of miRNA transcriptional regulation [36, 37] . miRNA-transcription factor feedback circuitries represent yet another layer of miRNA regulation. For example, O'Donnel et al. determined that the oncogene c-Myc is able to induce expression of a cluster of miRNAs on human chromosome 13 by binding to a putative promoter region upstream of the miR-17-92-20a cluster [38] . In this study, two of these miRNAs, miR-17-5p and miR-20a, were shown to negatively regulate the transcription factor E2F1, a target of c-Myc [38] . Transcription factor binding to miRNA promoters has also been extensively described as a critical factor in the regulation of several tissue-specific cell fates [39] . Specifically, a negative regulator of transcription and myogenesis, Yin Yang 1 (YY1) was shown to bind directly to several sites within the 20-kb region upstream of the miR29b/c transcription start site. YY1 is a potent inhibitor of myogenesis. In this specific case, YY1 and miR-29b/c create a negative feedback loop where YY1 is negatively regulated by miR-29b/c, which serves to alleviate miR-29b/c repression during myogenesis and enhance the effect of miR-29b/c on differentiation [39] .
miRNAs and proteins comprising the miRNA processor complex (Drosha, Dicer, Argonaute, among others) are also heavily regulated at the post-transcriptional level, and this serves as an additional layer influencing the final readout of miRNAs. Specifically, regulation of miRNA activity and stability can be influenced by post-translational modifications of Dicer and Argonaute proteins. Moreover, changes to accessory proteins that interact with Dicer and Argonaute may also affect the stability and final readout of miRNA activity under certain conditions [40] .
Pre-miRNA and mature miRNAs may be further cleaved or modified with sequence-specific alterations that could affect their stability or incorporation into the RISC and thereby affect their final targeting potential [41] . For instance, adenylation of the 3′ end of the mature miRNA increases stability [42, 43] , whereas uridylation at the 3′ end of miRNAs commonly decreases their stability [41, 44] . Interestingly, miRNA methylation seems to provide protection from 3′-end uridylation, [45] which would suggest a role for an increased stability of mature miRNAs.
Differential profiling of miRNAs
The use of high-throughput techniques (e.g., miRNA microarrays, Next-Gen Sequencing) has enabled the differential expression of miRNAs to be routinely identified in a variety of human diseases. For many years miRNA profiling using microarrays has been the most widely applied method for identifying differentially expressed microRNA; however, next-generation sequencing has recently emerged as a readily available research tool and is challenging the application of this enduring technique. In this section, we briefly review the most commonly used laboratory tools to identify miRNAs and then describe standard methods to validate and assess the functional significance of miRNAs in physiological and pathological conditions. miRNA microarray A key aspect of discovery-based designs in miRNA research has been global expression profiling of miRNAs to gain insight into the expression profiles of important miRNAs, enriched or severely dysregulated. Microarray technology has proven to be a critical tool in this context, and while not the perfect tool, it has served as a robust means of identifying dysregulated miRNAs.
In order to increase the sensitivity of miRNA microarrays, total RNA is initially enriched for small RNAs, since this class of RNA comprises a small proportion of total RNA. miRNAs are then 3′-end labeled with specific fluorophores and prepared for hybridization to miRNA arrays. These arrays are labeled with miRNA-specific probes that exhibit specificity for individual miRNAs and can be designed for speciesspecific analysis. Several challenges, however, exist when profiling miRNAs with this method. For example, a major shortcoming of microarrays is that since miRNA-binding affinity is different for each miRNA and its cognate probe, the probe hybridization for each miRNA may not be entirely specific or necessarily quantitative when assessed using miRNA microarrays. Another important limitation with miRNA microarray technology is that minor changes in miRNA levels, which could be biologically relevant, may not always be detectable. Such changes are great interest since although these less abundant miRNAs may not be detected based on microarray analysis, they may still serve as critical regulators of key genes in the context of a disease.
Next-generation sequencing
The relatively recent development of next-generation sequencing technologies has added an unprecedented scale and depth to miRNA profiling. High-throughput miRNA RNA sequencing (miR-Seq) technology has been developed to robustly annotate and quantify miRNA expression levels with a high degree of precision and sensitivity. Nextgeneration sequencing employs massively parallel sequencing, generating millions of reads per sequencing run. Its increased sensitivity bypasses the limitations of microarray technology and allows for the quantification and discovery of miRNAs present in very small quantities.
Briefly, total enriched miRNAs are size selected by gel electrophoresis and subjected to end repair and amplification, followed by the ligation of platform-specific adapters to the 3′ and 5′ ends of purified miRNA species and high-throughput sequencing. These reads are mapped back to the genome of interest, and abundance is quantified using several bioinformatics algorithms. The advent of readily accessible, highthroughput sequencing platforms (Illumina, Ion-Torrent) has greatly aided the research community with regards to the depth and sensitivity of global miRNA profiling and discovery. Currently, several companies (e.g., LC Sciences, Exiqon Inc. and ArrayStar Inc.) with expertise in non-coding RNA interrogation provide extensive miR-Seq services. A limiting step and a critical component of any successful miR-Seq project is a strong bioinformatics infrastructure, which is needed to accurately identify differentially regulated or novel miRNAs.
Validation of miRNAs
To validate the dysregulated miRNAs identified from miRNA profiling, researchers traditionally have used northern blotting, real-time polymerase chain reaction (PCR) and in situ hybridization to pinpoint the size, tissue distribution and localization of specific miRNAs. These techniques are especially useful in the kidney which has are several important cell compartments where miRNAs may be localized and differentially expressed. Following total RNA isolation, small RNAs, including miRNAs, are separated by gel electrophoresis and transferred to a nitrocellulose membrane. RNA is fixed to the membrane via UV crosslinking or baking. miRNA-specific probes are used to detect the miRNA of interest and exist in two primary types: poly-A tailed, hexamer-labeled miRNAspecific probes or locked nucleic acid (LNA; miRCury, Exiqon) miRNA-specific probes. Traditionally, both are 3′ end labeled with a [ 32 P]ATP radioactive probe and detected using X-ray films or phosphorimager systems.
In situ hybridization is another powerful tool to determine the localization and relative expression levels of miRNAs in a myriad of cell compartments and tissues and is particularly useful when the aim is to either quantify or determine the human pattern of expression of a specific miRNA of interest in preserved patient samples. To perform in situ hybridization assays, formalin-fixed, paraffin-embedded or frozen tissue sections are treated with a series of steps to reduce miRNA diffusion and loss during the in situ procedure. Sequencespecific miRNA probes are then hybridized based on the melting temperature ( T m ) calculated for each specific probe. LNA probes increase specificity and degree of detection and are a robust tool utilized in many in situ protocols. Probes can be labeled at the 5′ and 3′ ends with fluorophores to allow direct visualization following several wash steps, post-fixation and mounting. Alternatively, the probes may be labeled with small haptens, such as digoxigenin, either unconjugated or conjugated with alkaline phosphatase. These can be coupled to signal amplification systems; most commonly in the case of miRNAs, these include tyramide signal amplification systems [46, 47] .
The most commonly used method to detect specific alterations in miRNA levels, however, remains the utilization of quantitative real-time PCR. Because miRNAs are short, designing highly specific probes for their detection poses a challenge. Two general approaches are employed when performing reverse transcription, namely, microRNAspecific reverse transcription (RT) or universal RT. miRNAspecific RT utilizes stem-loop primers using a single-stranded region complementary to the 3′ end of the mature miRNA and a double-stranded universal primer region (stem) attached to this region that allows amplification of the specific miRNA under query. This miRNA-specific RT product can be used in quantitative PCR by taking advantage of miRNA-specific fluorescently labeled probes (Taq-Man, Life Tech) and a universal primer.
In the second approach, universal RT, poly-A tails are added to the 3′ end of all miRNAs present within a given RNA population, and these are subsequently amplified based on the Oligo(dT) universal primer which recognizes the 5′ end of the primer attached to the miRNA. This cDNA template is then used in quantitative PCR with miRNA-specific primers designed for quantitative PCR detection with SYBR Green, a fluorescent dye. The development of these off-the shelf assays has greatly aided the entire scientific community in creating extremely accessible reagents that facilitate the exploration of important questions related to miRNA research.
Identification of miRNA targets miRNAs are one of three classes of small, non-coding RNA; the others include PIWI-interacting RNAs (PIWIRNA) and small interfering RNAs (siRNA). All three classes recognize and bind to target mRNAs to inhibit gene expression.
Several bioinformatics and experimental approaches have traditionally been employed to identify novel and biologically relevant targets of miRNAs. The well-established, opensource bioinformatics tools include TargetScan (www. targetscan.org), miRANDA (www.microrna.org) and Pictar (www.pictar.mdc-berlin.de), among many others. These sites use miRNA seed sequence to predict their targets. The socalled seed sequence, a short continuous region of WatsonCrick base pairing between nucleotides 2-7 of the miRNA and complementary sequences in 3′-UTR regions of target mRNAs, determines the genes which could potentially be regulated by a specific miRNA.
The use of open-source bioinformatics tools, although indispensable in miRNA research, will only identify potential targets of a specific miRNA, and these potential targets must be each individually validated in the context of a stimulus and cell/tissue-specific conditions. More importantly, these computational resources will not validate the in vivo interaction between a specific miRNA and its potential target nor it will reveal novel targets for a miRNA. In this regard, experimental de novo identification of miRNA targets has been greatly aided by the ability to capture and quantify specific miRNA-mRNA interactions by a number of newly developed techniques. The most widely adapted technique, CLIP (RNA Crosslinking and Immunoprecipitation), has been coupled with high-throughput sequencing to facilitate the identification of novel miRNA binding sites throughout the genome. Several variations have been utilized, but all rely on the same principle of purifying Argonaute-miRNA and ArgonautemRNA interactions to generate genome-wide interaction profiles of miRNA-mRNA interactions in vivo. The first widely employed method, HITS (high-throughput sequencing)-CLIP, established the feasibility of this technique to generate meaningful miRNA-mRNA interaction profiles [48] . A second technique that is commonly employed, iCLIP (individualnucleotide resolution)-CLIP, generates extremely precise data to help map miRNA-mRNA interactions at a single basepair level by circularization of the purified sequences followed by restriction digest linearization and library preparation. This technique identifies, with great precision, the site of the miRNA and mRNA interactions [49] . Another method to precisely identify crosslinking sites and increase crosslinking efficiency, PAR (photoactivatable-ribonucleoside)-CLIP, utilizes photoactivatable 4-thiouridine (4SU), which when excited by UV spectra at 365 nm contributes to enhanced crosslinking efficiency. Sequenced cDNA prepared from these reactions is scored for the conversion of thymidine to cytidine, indicating a unique crosslinking site [50] . These interactions can be further verified by RNA-IP experiments, followed by RNA purification, cDNA synthesis and genespecific quantitative RT-PCR.
A powerful proteomic approach, stable isotope labeling by amino acids in cell culture (SILAC), has recently been employed to identify novel targets of miRNAs. SILAC employs the global incorporation of isotope-labeled amino acids (typically lysine, arginine, with 13 C 6 or 15 N 4 ) into all proteins synthesized under those specific culture conditions. Following treatment with the miRNA of interest, these "heavy" protein populations are intermixed with cells cultured in "light" isotope conditions and treated with control mimics. Protein lysates are subjected to gel electrophoresis and mass spectrophotometry analysis, and the relative peak intensities of each distinctly labeled peptide are used to quantify protein abundance in each experimental group. "Heavy"-labeled proteins which exhibit significantly reduced peak intensity compared to "lightly" labeled controls, are subject to further bioinformatics analysis to identify the presence or absence of the desired miRNA target site. SILAC permits relative quantification of the proteome between "heavy" and "light" samples and is a powerful tool to identify unique miRNA targets acting at the level of protein translation, the ultimate final output of miRNA activity.
A commonly used method to validate the effect of miRNAs on a specific target is the gene reporter assay where the wildtype 3′-UTR of the proposed mRNA target gene is cloned within the 3′-UTR of a gene reporter, most commonly luciferase. This construct along with the miRNA of interest is subsequently overexpressed within cells, and reporter activity is then measured. Typically, inhibition of luciferase activity is observed in cells overexpressing the wild-type 3′-UTR and miRNA of interest, when compared to a nontargeting control miRNA, suggesting that the mRNA could be a strong target of the miRNA [51] .
An additional biochemical approach to verify the nature of a miRNA and the potential target involves the use of miRNA target site protectors. These are short oligonucleotides designed against a specific miRNA binding site within the 3′-UTR of the putative target mRNA. Once bound, the target site protector prevents interaction of the miRNA and its target mRNA, and hence it will determine whether a specific miRNA-dependent phenotype is due to a potential target of that miRNA. An advantage to this approach is that it reduces the ambiguity regarding the off-target effects of miRNA and limits analysis to a single miRNA target [52, 53] .
Manipulating microRNA levels in vitro and in vivo
A single miRNA may exert regulatory effects on a number of target genes and related biological pathways [54, 55] . The pleiotropic nature of miRNAs allows for robust and extremely penetrant gene regulation within the context of normal and pathological processes. This is indeed one of the main advantages of targeting miRNAs, since each miRNA targets several coding and non-coding genes that are involved in many pathways critical in human pathologies. Furthermore, understanding the function of miRNAs lies in the ability to identify the direct and indirect targets of a specific miRNA and characterize numerous genes that a single miRNA can target by using several of the in vitro and in vivo tools described below.
Although researchers have just begun to understand the full range of biological functions of miRNAs, the ability of miRNAs to target multiple genes and pathways has created significant interest in their potential for therapeutic applications. Indeed, restoring or repressing miRNA expression has proven to be extremely useful as potential therapeutic applications within various pathological states.
The traditional and dominant in vitro form of miRNA manipulation has been through the use of miRNA mimics to restore miRNA levels or antisense miRNAs to block miRNA function. miRNA mimics are double-stranded synthetic oligonucleotides manufactured as either the pre-miRNA or the mature miRNA, which are processed into a single-stranded form in the cell to mimic the effect of miRNAs. Several strategies are currently under intense investigation with the aim to enhance the stability of miRNA mimics and protect them from degradation. These include several lipid-based delivery reagents and formulations of inorganic and/or organic nanoparticles, namely modified polymers such as polyethylenimine, polyethylglycol and polylactide-co-glycolide. These, in theory, should allow for less frequent dosing and may avoid the need for continuous infusions [56] .
Similarly, antisense oligonucleotides (anti-miRs) are commonly used to block the effect of miRNAs. Anti-miRs include LNA-anti-miRs, antagomirs and miRNA sponges. The antimiRs are designed against the mature miRNA sequence and sequester miRNA from incorporation into the RISC complexes. Several modifications mainly directed to the 2′-OH, 4′-hydrogens and α-oxygen of the phosphate group and the amide linkage between ribose and base have been designed to overcome the poor stability of miRNA for cell and tissue delivery. Examples of commonly used modifications include: LNA modification which links the 4′-C of ribose with 2′-OH; modifications at the 2′-OH group, including 2′-Omethoxyethyl and 2′-O-methyl and 2′-fluoro; replacement of t h e α -o x y g e n o f t h e p h o s p h a t e g r o u p w i t h methylphosphonate, phosphothiorate and boranophosphate groups [56] . These modifications in vivo will provide protection against exonuclease activity, reduce the inflammatory response, increase tissue/cell uptake and enhance targeting efficacy. To date, only a single LNA-anti-miR has progressed through clinical trials-the liver-specific LNA-anti-miR-122, miravirsen, developed and tested by Santaris Pharma (Copenhagen, Denmark), is currently being tested for the treatment of hepatitis C.
Antagomirs are cholesterol-conjugated synthetic RNAs with a 2′-O-methoxyethyl linkage and phosphorothioate modification, whereas miRNA sponges are multiple short tandem repeats of the miRNA target site cloned as the 3′-UTR of a reporter gene within a plasmid, retrovirus or lentivirus. Once expressed within the target cell type or tissue, miRNAs preferentially bind the sponge and are prevented by interacting with the RISC, thereby sequestering their ability to inhibit true endogenous mRNA targets [57] .
Extensive studies have convincingly shown the feasibility and therapeutic efficacy of miRNA inhibition within the kidney from several groups [58] [59] [60] . However, miRNA replacement within the kidney in vivo is less well investigated. To the contrary, there are several studies that have shown the feasibility of miRNA replacement in other model systems. For example, Liu et al. investigated the therapeutic efficacy of miR-34 replacement within prostate tumors with increased expression of CD44, a key marker of malignant prostate cancer stem cells [61] . These authors found that coupling miR-34 with a lipid-based delivery agent administered systemically via tail vein injection to NOD-SCID mice was sufficient to reduce tumor burden, metastatic potential and increase overall survival probability compared to mice injected with non-specific controls. Similarly, in a separate study, systemic miR-34a and miR-143/145 restoration was used to effectively reduce tumor burden in mice with pancreatic cancer xenografts [61] . These putative miRNA tumor suppressors were coupled with lipid-based nanoparticles (nanovectors) and systemically administered to mice harboring either subcutaneous or orthotopic xenografts. Tumor growth was blocked and increased apoptosis and decreased proliferation were achieved in these tumor models. At the present time, MRX34 (Mirna Therapeutics, Austin, TX), a liposome-formulated miR-34 mimic, is the first miRNA mimic to enter clinical trials for patients with unresectable primary liver cancer or advanced metastatic cancer with liver involvement.
A potential downside effect of miRNA manipulation in vitro and in vivo is the off-target effects induced by the modulation of multiple miRNA targets. Specifically, antagomirs may target related miRNAs of a specific cluster or family, since many of these miRNAs exhibit strong sequence homology. Similarly, miRNA replacement therapy may result not only in the downregulation of the intended target but also in the modest downregulation of several other genes, which may have undesirable consequences. Lastly, the distribution of tissues involved in pharmacological miRNA manipulation suggests that other tissues, besides the desired tissue, may incorporate and affect miRNA levels and activity in a negative manner.
miRNAs and kidney homeostasis
Thus far, we have described the framework for understanding what miRNAs are, how they elicit their potent gene regulatory activity and how we detect and target specific miRNAs to unravel precise mechanisms related to interesting miRNAs and observed phenotypes. We now shift our focus to understand the impact of miRNAs on kidney-related research in physiological and pathological conditions. Several research groups highlighted the importance of miRNAs to normal kidney homeostasis when they set out to genetically delete Drosha and Dicer in podocytes [62] [63] [64] [65] . Taken together, their observations demonstrate that a global knockdown of miRNA levels leads to significant proteinuria and podocyte effacement as early as 3 weeks, followed by glomerulopathy, reduced slit diaphragm protein (nephrin and podocin) expression, proteinuria and renal failure [62] [63] [64] [65] .
Several additional studies investigated the role of Dicer in specific kidney compartments. Among these, Patel et al. demonstrated that the deletion of Dicer in maturing renal tubules and the ureteric bud stalk for up to embryonic day 17.5 in mice leads to severe tubular and glomerular cysts, mediated in part by the downregulation of miR-200 family members, of which miR200b/c and -429 were shown to target the polycystic kidney disease type 1 gene Pkd1 [66] . Consistent with the severe phenotype observed upon Dicer deletion in the developing kidney, Sequeira-Lopez et al. observed that conditional deletion of Dicer in juxtaglomerular cells reduced the number of these cells present in the adult kidney, accompanied by a significant decrease in renin expression (Ren1 and Ren2), with the subsequent reduction of plasma renin levels, and reduced blood pressure [67] . These authors also observed that the deletion of Dicer in juxtaglomerular cells gave rise to vascular abnormalities and striped fibrosis. Conversely, conditional deletion of Dicer in adult renal proximal tubules does not result in a severe phenotype; in fact, these mice were found to exhibit normal kidney development, morphology, histology and function [68] . Interestingly, when stressed by ischemia [kidney ischemia/reperfusion (I/R) model], these mice exhibited renoprotective features, namely improved kidney function, histology and increased survival [68] . Such studies serve to highlight the diverse effect of miRNAs in different kidney cell types.
We now explore the role of several well-established miRNAs involved in the pathophysiology of a variety of kidney diseases. These selected miRNAs are summarized in Table 1 , and while our list is not exhaustive, it does provide an introductory framework to understand the importance of miRNAs in the pathophysiology of several kidney diseases.
Focal segmental glomerulosclerosis
Several studies have investigated the potential role of miRNAs as biomarkers to predict focal segmental glomerulosclerosis (FSGS). However, until only very recently, only a few functional studies have investigated the impact of miRNA dysregulation on the pathogenesis and progression of FSGS.
While searching for miRNAs that could affect breast tumorigenesis, Gebeshuber et al. unexpectedly observed that conditional overexpression of miR-193a is able to phenocopy features of FSGS [69] . To determine whether the cause of miR-193a-induced FSGS is an aberrantly secreted factor, the authors transplanted a single transgenic kidney into a wild-type animal and subsequently observed selective induction of FSGS in the transgenic kidney only. The reciprocal transplantation experiments confirmed that miR-193a-induced FSGS does not result from the secretion of a pathogenic factor, but rather from exclusive overexpression of miR-193a. To delineate the mechanism which caused the induction of FSGS, the authors compared significantly downregulated RNA-Seq gene expression signatures from glomeruli of transgenic mice against a list of previously described genes downregulated in human cases of FSGS. From this analysis, Wilm's tumor gene (WT-1) was shown to be a direct target of miR-193a. Importantly, podocyte-specific 
miRNA, MicroRNA WT1, Wilms tumor tumor suppressor gene; SIP1, survival of motor neuron interacting protein-1; SOD, superoxide dismutase; VEGF-A, ascular endothelial growth factor A; PPARα, peroxisome proliferator-activated receptor alpha; BMP, bone morphogenetic protein; BMPR1B, Bone morphogenetic protein receptor type-1B; PKD 1, 2, olycystic kidney disease type 1, type 2; STAT, oncogenic transcription factor; EYA1, eyes absent homolog 1; SIX1, transcription factor deletion of WT-1 resulted in a similar phenotype observed upon miR-193a overexpression. Finally, the authors discovered that miR-193a was significantly overexpressed in patients diagnosed with several histological subtypes of FSGS when compared to either healthy individuals or individuals with other primary glomerular diseases (IgA nephropathy, minimal change disease, membranous nephropathy) [69] . This detailed study merits further work to determine if miR-193a is a prime therapeutic target for patients with FSGS. In a separate study, Wu et al. recently discovered that members of the miR-30 family underwent significant downregulation in human podocytes treated with several factors known to induce podocyte injury, including transforming growth factor beta (TGF-β)), lipopolysaccharide or puromycin aminonucleoside (PAN) [70] . Interestingly, the miR-30 is among the most highly expressed miRNAs within the podocyte. This significant downregulation seems to contribute to TGF-β-or PAN-induced podocyte cytoskeletal damage and apoptosis. These features associated with FSGS were attenuated upon overexpression of miR-30 family members, accomplished via glucocorticoidmediated induction of miR-30 [70] .
Diabetic nephropathy
Diabetic nephropathy (DN) is the most common cause of endstage renal disease in the USA. There is increasing experimental data to implicate miRNAs as essential factors in the progression of DN, and they may possibly also serve as key targets of therapy.
The Natarajan research group was the first to identify a group of differentially dysregulated miRNAs in glomeruli from type 1 (STZ) and type 2 diabetic mice (db/db), as well as in mesangial cells cultured under high glucose conditions [71] . Based on the results of this screening, the authors focused on miR-192, which has since become one of the more prominently studied miRNAs within the DN field. miR-192 was shown to regulate the proliferation of kidney mesangial cells via downregulation of survival of motor neuron interacting protein-1 (SIP1). Repression of SIP1 by miR-192 was shown to increase collagen in response to TGF-β1/SMAD signaling. In subsequent studies, this group continued on to comprehensively dissect the role of miR-192 at the molecular level [72] , ultimately showing that inhibition of miR-192 with exogenously administered LNA-miR-192 antagomirs in STZ diabetic mice is renoprotective against features of DN [58] . These studies were later corroborated when global genetic deletion of miR-192 proved to be similarly renoprotective in diabetic mice [73] .
Several recent studies, including data from our own laboratory, have further characterized the role of miRNAs in the homeostasis of podocytes and glomerular endothelial cells in different models of DN. We have shown that two miRNAs, miR-93 and miR-29c, are significantly dysregulated within the diabetic environment in podocytes and glomerular endothelial cells, both in vitro and in vivo. Using comparative miRNA microarrays, both miR-93 and miR-29c were identified as signature miRNAs in hyperglycemic conditions [59, 74] . miR-93 levels were significantly lower in glomeruli from type 2 diabetic db/db mice than in the glomeruli of controls and in high glucosetreated podocytes and renal microvascular endothelial cells. In contrast, miR-29c levels were significantly increased in glomeruli obtained from diabetic db/db mice. Vascular endothelial growth factor A (VEGF-A) was identified as a relevant target of miR-93 with a known role within the kidney. Further, a wellconserved miR-93 binding site was identified within the 3′-UTR of vegf-a. Using transgenic mice containing VEGF-LacZ bicistronic transcripts, we demonstrated that inhibition of miR-93 by peptide-conjugated morpholino oligomers elicited an increased expression of VEGF [74] . Meanwhile, miR-29c was found to induce podocyte apoptosis. Overexpression of miR29c decreased the levels of Spry1 protein, a direct target of miR29c, and promoted activation of Rho kinase. Importantly, knockdown of miR-29c by a specific antisense oligonucleotide significantly reduced albuminuria and kidney mesangial matrix accumulation in the db/db mouse model in vivo [59] . Alternatively, several studies have found that the miR-29 family is repressed under hyperglycemic conditions, most notably miR-29a and -b in tubular epithelial cells and mesangial cells [75] . These contrasting results can, at least partially, be explained by cell typeand stimulus-specific differences among the studies, since many of the studies demonstrating reduced miR-29 family expression were carried out in mesangial and tubular epithelial cells, as well as within the context of the TGF-β1 signaling cascade a wellknown pathogenic mediator of diabetic nephropathy and tubulointerstitial fibrosis.
Finally, Wang et al., found miR-377 to be a key miRNA upregulated by high glucose and TGF-β1 of mesangial cells and in type 1 diabetes. These authors demonstrated that miR-377 overexpression contributes to increased fibronectin 1 expression and oxidative stress via repression of the target Pak1 and superoxide dismutase [76] .
Kidney fibrosis
Many studies investigating the role of miRNA in kidney fibrosis have focused on the activated myofibroblasts in primarily two models of murine kidney fibrosis: the unilateral ureteral obstruction (UUO) model and the I/R model.
Among the several miRNAs that have emerged as central regulators of renal fibrosis, miR-21, a TGF-β1-induced miRNA, has attracted a great deal of attention. miR-21 was initially shown to play a role in heart fibrosis [77] . Elevated miR-21 levels were similarly observed in idiopathic lung fibrosis, and inhibition of miR-21 in mouse models of lung fibrosis ameliorated this phenotype [78] . The role of miR-21 in kidney fibrosis has been demonstrated in several ways: (1) miR-21 expression levels are dramatically induced in patients in patients with chronic kidney disease [79, 80] ; (2) miR-21 expression is dramatically elevated in several experimental models of kidney fibrosis, including the UUO, I/R and DN models of fibrosis [60, 81, 82] ; (3) a more recent study investigating the role of miR-21 deletion in mouse models of fibrosis (UUO and I/R) revealed that miR-21 deletion significantly improves features of interstitial fibrosis. Indeed, miR-21 contributes to kidney fibrosis by targeting peroxisome proliferator-activated receptor alpha (PPARα), a key regulator of lipid metabolic pathways, and Mpv171, an inhibitor of mitochondrial specific reactive oxygen species [83] .
Our own group recently identified miR-22 as a master regulator of kidney fibrosis by targeting several bone morphogenetic protein (BMP) family members. Based on several screens of putative BMP-7/6 miRNA regulators, we demonstrated that miR-22 is a potent regulator of BMP-7/6 genes at both the protein and mRNA levels. To investigate the functional significance of this targeting cascade, we used miR-22 knockout mice and found that key features of fibrosis were significantly attenuated using the UUO model of kidney fibrosis. At the molecular level, we identified several BMP responsive elements within the proximal promoter region of the miR-22 host gene and demonstrated that BMP-7/6 are able to induce miR-22 expression directly [84] .
Polycystic kidney disease Several miRNAs have been described to target both PKD1 (encoding polycystin 1) and PKD2 (encoding polycystin 2). Among these miRNA, members of the miR-17-92 family have been highlighted as key mediators of the pathogenesis and progression of PKD. miR-17 was the first miRNA implicated in the regulation of PKD2 expression [85] . Shortly following the publication of these results, two groups independently of each other revealed that bicaudal 1 (Bicc1) mutant mice developed fluid-filled cysts within the kidney that were reminiscent of PKD [86, 87] . These authors demonstrated that the Bicc1 gene regulates the mRNA stability and translation efficiency of PKD2 and also antagonizes the repression of PKD2 by miR-17, resulting in increased PKD2 expression.
Patel et al., followed up on their earlier Dicer knockout studies within the kidney to demonstrate significant upregulation of the entire miR-17-92 family (miR-17, −18a, −19a, −19b, −20a, −92a) in several mouse models of PKD. They showed that kidney tubular-specific overexpression of the family leads to cyst development within the kidney and that kidney-specific genetic ablation of the family leads to reduced cyst development in a mouse model of PKD. These actions were mediated in part through PKD1, PKD2 and hepatocyte nuclear factor-1β [88] . These results suggest that this family of miRNAs may serve as a potential therapeutic target for patients with PKD.
The specific role for miRNAs within autosomal recessive polycystic kidney disease (ARPKD) has also been described. Lee et al. reported that miR-15a is associated with hepatic cystogenesis in the PCK cholangiocyte cell line derived from the rat model of ARPKD and in liver tissue from patients with polycystic liver disease [89] . Further studies are required to relate these findings to the role of miR-15a in ARPKD. Finally, miR-365-1 has recently been shown to inhibit the expression of polycystic kidney and hepatic disease 1 (PKHD1) [90] ; however, further studies are required to fully elucidate the role miR-365-1 within ARPKD.
Wilms tumor
Recently, several mutations have been identified in Dicer1, the key miRNA-processing enzyme, in patients with Wilms tumor (WT), heavily implicating the broad role of miRNA dysregulation in WT. One of the most notable observations is that the Oncomir-1 cluster of miRNAs is significantly increased in patients with Wilms tumor and that this increase correlates with elevated expression levels of the transcriptional regulator of Oncomir-1, E2F3 [91] . Similarly, the oncogenic transcription factor STAT3 is capable of inducing miR-370 expression, which in turn inhibits expression of WTX (Wilms tumor gene on the X chromosome), a commonly inactivated tumor suppressor in Wilms tumor [92] .
Interestingly, in a separate study, Drake et al. identified the kidney-specific miR-562 within the 2q37.1 region to be reduced in Wilms tumor patients. The target of miR-562, EYA1 (eyes absent homolog 1), is critical in kidney development, and its misregulation during development in these patients may contribute to tumor pathobiology [93] .
Finally, Six1 is a critical transcription factor that coordinates several developmental programs, including programs within the kidney. Six1 is frequently upregulated in adult and pediatric malignancies, including Wilms tumor. Imam et al. found that expression of a putative miRNA regulator of Six1, miR-185, is frequently reduced in these malignancies, including Wilms tumor. Several experiments revealed that restoration of miR-185 expression is capable of reducing tumorigenicity of cancer cells both in vitro and in vivo [94] . While good progress has been made thus far, there is still a need to better understand the role of miRNAs in this rare patient population.
Renal cell carcinoma
Extensive studies have been dedicated to unraveling the role of miRNAs in renal cell carcinoma (RCC), including comprehensive analysis from The Cancer Genome Atlas (TCGA) consortium [95] . Most notably, miR-21, miR-34a, miR200c, miR-215 and miR-17-5p have been characterized as promising biomarkers and possibly therapeutic targets for RCC. However, additional in vivo work with a robust mouse model or xenograft model of RCC is needed to further validate many of these initial findings primarily made in in vitro conditions.
Future challenges
Within a relatively short time frame, kidney researchers have made impressive strides in delineating the potential impact of a number of miRNAs as key regulators of physiological and pathological processes in the kidneys. The relatively stable nature of miRNAs and the many recent advancements in their isolation, purification and detection methods have made the feasibility of utilizing miRNA as biomarkers in human disease samples an impending reality. Indeed, several research groups have investigated the release and quantification of miRNAs in the blood and urine of patients with different kidney diseases as new potential biomarkers [96, 97] . These studies are promising and continued exploration into the possibility of circulating miRNAs as predictive factors for kidney disease is important. However, despite significant progress, many challenges still remain before we can successfully employ miRNAs as potential therapeutic targets. For example, the effect of a miRNA can be cell-and stimulus-specific, where the same miRNA can have different targets in the same organism with potentially opposite effects in different cells. Therefore, modulating miRNAs may result in beneficial effects in one cell type but harmful effects in another. Furthermore, another substantial challenge associated with the miRNA-targeted approach is the delivery of miRNAs. Delivery systems and the ability to manipulate miRNAs in humans will continue to be the critical elements to bringing miRNAs from bench to bedside. 
